Overview
Diagnosing and Treating Women with IDA: What Every Clinician Needs to Know
HCP-focused whiteboard
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This short animated HCP-focused whiteboard aims to improve screening and clinical management of iron deficiency (ID) and iron deficiency anemia (IDA) in women across diverse clinical settings to improve patient outcomes.
This activity is intended for obstetricians/gynecologists, primary care providers, ED clinicians, and other healthcare providers treating patients with IDA.
Clinicians who treat women need to be aware of the risk factors, the causes, and the clinical implications signs and symptoms of iron deficiency (ID)/iron deficiency anemia (IDA), as well as the recommended screening tools to support their timely diagnosis and the optimal treatment selection. It is important for clinicians to be competent in clinical management of ID/IDA in women across diverse clinical settings to improve patient outcomes.
Upon completion of this activity, participants will be able to:
• Describe the impact of undertreated iron deficiency (ID) and iron deficiency anemia (IDA) in women
• Discuss the relationship of heavy menstrual bleeding (HMB) to ID and IDA
• Introduce evidence-based screening practices for women at risk for ID and IDA
• Assess and develop optimal treatment options for IDA based on clinical severity, efficacy, routes of administration, and clinical appropriateness
• Describe the impact of undertreated iron deficiency (ID) and iron deficiency anemia (IDA) in women
• Discuss the relationship of heavy menstrual bleeding (HMB) to ID and IDA
• Introduce evidence-based screening practices for women at risk for ID and IDA
• Assess and develop optimal treatment options for IDA based on clinical severity, efficacy, routes of administration, and clinical appropriateness
Supported by an educational grant from American Regent.
Malcolm G. Munro MD, FACOG, FRCSC
Chair, Women's Health Research Collaborative (WHrC)
Immediate Past Chair, FIGO Menstrual Disorders Committee
Clinical Professor, Department of Obstetrics & Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Chair, Women's Health Research Collaborative (WHrC)
Immediate Past Chair, FIGO Menstrual Disorders Committee
Clinical Professor, Department of Obstetrics & Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Malcolm G. Munro MD, FACOG, FRCSC (Faculty)
Advisor or Review Panel Member: Daiichi-Sankyo, Hologic, Myovant Sciences, Pharmacosmos, Vifor
Consultant (Occasional): AbbVie, American Regent, Coopersurgical, Hologic, Myovant Sciences, Vifor
Grant/Search Support Recipient: AbbVie and Pharmacosmos
Speaker Bureau: Daiichi-Sankyo
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
